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Summary
In Brazil, approximately 130 new cases of hepatitis A
per 100,000 inhabitants occur annually and 15% of
the population has been in contact with hepatitis B vi-
rus. Portal hypertension causes hypersplenism and redu-
ces T cell production, which may lead to less effective
response to hepatitis vaccination. The objective of the
study was to evaluate the response to hepatitis A and B
vaccination in patients with portal hypertension secon-
dary to chronic liver disease or portal vein thrombosis.
Twenty-three patients (2 to 18 years) with portal hy-
pertension seen at the Pediatric Hepatology Service of
Hospital das Clínicas, Universidade Estadual de Cam-
pinas, between 1994 and 2006 were studied. Hepati-
tis A and B serology was tested in all patients. Patients
who had not been vaccinated before their visits received
the vaccines during the study period. Patients who had
been vaccinated before but had negative anti-HB anti-
bodies received a booster dose, and their serology was re-
peated. Blood counts were performed in each patient to
assess for immunosuppression. Eighteen patients recei-
ved hepatitis A vaccine and all became positive for an-
ti-HAV antibodies. All patients had received hepatitis
B vaccine and 17 (73.9%) were anti-HBs positive at
the time of the study. The other 6 received a booster do-
se and became anti-HBs positive afterward. The anti-
HBs-positive and -negative patients did not differ sig-
nificantly in age, leukocytes, lymphocytes, or duration
between the vaccination and positive serology. In this
study, hepatitis A vaccines elicited a 100% response
and hepatitis B vaccine conferred protection and indu-
ced an anamnestic response in pediatric patients with
portal hypertension.
Key words: portal hypertension, hepatitis A, hepatitis
B, vaccine, children, adolescents.
Títulos de anticuerpos y respuesta a
la vacunación contra hepatitis A y B
en pacientes pediátricos con
hipertensión portal
Resumen
Anualmente ocurren en Brasil aproximadamente 130
casos nuevos de hepatitis A, por 100.000 habitantes.
Se cree que el 15% de la población haya estado en con-
tacto con el virus de la hepatitis B. La hipertensión
portal puede llevar al hiperesplenismo con reducción de
células T, pudiendo disminuir la respuesta a la vacu-
nación. El objetivo del presente estudio es evaluar la
respuesta a la vacunación contra las hepatitis A y B, en
la hipertensión portal secundaria a la hepatopatía cró-
nica o trombosis de la vena porta. Se evaluaron 23 pa-
cientes (2-18 años) con hipertensión portal atendidos
en el servicio de Hepatología Pediátrica del Hospital de
Clínicas de la Universidad Estadual de Campinas,
desde 1994 hasta el 2006. Las serologías fueron reali-
zadas en todos los pacientes. Los individuos no vacuna-
dos recibieron las vacunas durante el estudio. Los pa-
cientes anti-HBs negativos recibieron refuerzo y la se-
rología fue repetida. Valoraciones hematimétricas fue-
ron realizadas para evaluar alteraciones recurrentes de
la inmunosupresión secundaria a la enfermedad de ba-
se y al hiperesplenismo. Dieciocho pacientes recibieron
vacuna contra la hepatitis A y presentaron respuesta.
Todos los pacientes recibieron 3 dosis de la vacuna con-
tra la hepatitis B, y diecisiete (73,9%) presentaron res-
puesta. Seis fueron sometidos a refuerzo y todos presen-
taron anti-HBs positivo. No hubo diferencias estadísti-
camente significativas entre los anti-HBs positivos y
negativos con relación a edad, leucocitos, linfocitos,
tiempo entre las vacunas y la realización de la serolo-
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gía. Se concluye que la vacuna contra la hepatitis A
presentó 100% de respuesta en pacientes con hiperten-
sión portal mientras que la vacuna contra la hepatitis
B les proporciona protección y les induce respuesta
anamnésica.
Palabras claves: hipertensión portal, hepatitis A, hepa-
titis B, vacuna, niños, adolescentes.
In Brazil, approximately 130 new cases of hepati-
tis A virus (HAV) infection per 100,000 inhabitants
occur annually, and the country is considered a
high-risk area for contracting the disease.1 Vaccina-
tion is indicated for groups at high risk of infection,
including individuals traveling from low endemicity
areas to intermediate or high endemicity areas, ho-
mosexual men, intravenous drug users, individuals
with a high occupational risk for infection, indivi-
duals with coagulation factor disorders, and patients
with chronic liver disease.2
Patients with chronic liver disease have a higher
mortality rate and a higher incidence of fulminant
hepatitis when infected with HAV, and thus should
receive vaccination.3-5 Hepatitis A vaccine is safe and
well tolerated and has an extremely high immuno-
genicity with 98.2% to 100% of healthy individuals
developing protective antibody levels after two do-
ses of the vaccine within an interval of 6 months.4,6
There are at least 350 million people infected with
hepatitis B virus (HBV) worldwide and approxima-
tely 2 billion have come in contact with the virus. In
Brazil, the Ministry of Health estimates that at least
15% of the population has been in contact with the
virus and that 1% has chronic disease.7 High-risk
areas in Brazil include the western part of the State
of Paraná and some Amazon regions.8 About 1 mi-
llion chronically infected people die each year from
chronic liver disease through cirrhosis and hepatoce-
llular carcinoma.9 Prevention of hepatitis B should
be started at birth, with a series of three vaccine do-
ses completed at 6 months of age. Vaccination
against hepatitis B has been implemented since the
1980s, and the vaccine is one of the safest available.10
No response to hepatitis B vaccine is observed in
3% to 5% of healthy individuals, which may be asso-
ciated with the frequency of some HLA class II alleles,
such as HLA-DRB1*0301, DRB*0701 and DQA2
in recipients.11,12 A lower response to the vaccine has
also been demonstrated in patients with chronic liver
disease as well as in immunosuppressed patients.13-15
Portal hypertension is characterized by increased
blood pressure in the portal venous system at least
10mmHg higher than normal and is frequently as-
sociated with chronic liver disease. However, extra-
hepatic portal vein obstruction has been linked to
portal hypertension in pediatric patients.16,17 Spleno-
megaly is the most prominent sign of portal hyper-
tension, which is a result of hypersplenism due to fi-
brocongestive alterations of the spleen.16,18,19 Hypers-
plenism is characterized by the sequestration and
destruction of red blood cells, leukocytes and plate-
lets due to spleen enlargement, and hyperplasia of
the respective precursors of the depleted cells due to
blood cytopenia after splenectomy.20 Because the
immunological memory depends on T lymphocy-
tes, the response to vaccination may be reduced in
children with hypersplenism.
The objective of the present study was to evaluate
antibody response to vaccination against hepatitis A
and B in pediatric patients with portal hypertension
secondary to portal vein thrombosis or chronic liver
disease.
Patients and methods 
Patients
Included in the study were patients who were
treated at the Pediatric Hepatology Service of Hos-
pital de Clínicas, UNICAMP (HC-UNICAMP)
between 1994 and 2006. They must be younger
than 18 years and have a diagnosis of portal hyper-
tension established by ultrasonographic criteria
(presence of splenomegaly, gallbladder wall thick-
ness, lesser omental thickness at the venous liga-
ment, lesser omental to aorta ratio, presence of sple-
norenal shunt) 21-24 and/or by presence of the esop-
hageal varices.
Twenty-three patients ranging in age from 2 to 18
years (mean: 9.5 years, median: 9 years) with an ul-
trasonographic diagnosis of portal hypertension we-
re included in the study. Fourteen (60.9%) of these
patients were boys.
Sixteen (69.6%) of the 23 patients had a diagno-
sis of portal vein thrombosis and seven (30.4%) had
chronic liver disease diagnosed by liver biopsy. The
causes of chronic liver disease were congenital hepa-
tic fibrosis in five patients and idiopathic in two. All
patients were serologically negative for HIV, hepati-
tis C and hepatitis B (HBsAg and anti-HBc). 
Exclusion criteria were the presence of positive se-
rology for hepatitis B, hepatitis C or HIV, chronic
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renal failure, diabetes mellitus, or diseases or medi-
cations resulting in immunosuppression. Patients
with autoimunne hepatitis and Wilson’s disease we-
re also excluded from the study.
Methods
The study was approved by the Ethics Committee
of Faculdade de Ciências Médicas, UNICAMP, and
all patients participated in the study after the parents
and guardians had signed the informed consent form. 
All patients had serological tests for hepatitis A
and B. Serology was performed by a microparticle
enzyme immunoassay (MEIA) using the AXSIM®
automatic system (Abbot, Wiesbaden, Germany).
Serology for hepatitis A was qualitative, and hepati-
tis B antibody level was quantitatively determined
using the AUSAB® kit. Samples presenting anti-
HBs with a concentration of 10 mIU/mL or higher
were considered to be reactive.
Patients not previously vaccinated received the
vaccines during the study period. Previously vacci-
nated patients with a negative result for anti-HBs
received a booster dose, and their serology was re-
peated after the booster.
The following hepatitis A vaccines were used:
Havrix® (720U, SmithKline Beecham Biologicals)
and Berna® laboratory vaccine (0.5mL). Two doses
were administered at an interval of 6 months. The
recombinant Euvax® vaccine was used for vaccina-
tion against hepatitis B (10µg HBsAg/0.5mL, LG
Chem) and was given at 0,1 and 6 months. 
Blood counts were performed at the same time as
the serological tests to identify immunosuppression
secondary to the underlying disease and hypersple-
nism. Leukopenia was classified as an absolute num-
ber of leukocytes less than 4000/mm3, and lymp-
hocytopenia was defined as an absolute number of
lymphocytes less than 1500/mm3.25
For comparative analysis, patients were divided
into two groups: group A consisted of those with
portal vein thrombosis and group B included those
with chronic liver disease.
The results are presented as descriptive analysis
including frequencies for categorical variables and
measures of position and dispersion for continuous
variables. Continuous or ordinal variables were
compared between the two groups using the Mann-
Whitney test with a level of significance set at 5%.26
The SPSS for Windows program, version 7.5, was
used for analysis of the data.
Results
Five of the 23 patients presented serology indica-
ting natural immunity against HAV (mean age: 11
years and 9 months, median: 13 years); the other 18
patients had negative serology results and received
the hepatitis A vaccine. Eleven patients received the
Havrix® vaccine and 7 were vaccinated with the Ber-
na® laboratory vaccine.
All patients received the primary vaccination se-
ries for hepatitis B, with 11 being vaccinated at the
Immunobiology Sector of HC-UNICAMP (recom-
binant Euvax® vaccine), and 12 at community
health centers in their towns. The first assessment
after the vaccination showed that 17 (73.9%) pa-
tients became anti-HBs positive.
Blood counts were performed at the same time as
the serological tests. Two patients had anemia, leu-
copenia, and thrombocytopenia resulting from hy-
persplenism; 11 had lymphocytopenia only.
Group A: Nine (56.3%) of the 16 patients with
portal vein thrombosis were male. The age and hema-
tological characteristics of the patients are shown in
Table 1. Two (12.5%) patients presented natural im-
munity against hepatitis A. The other patients recei-
ved the hepatitis A vaccine, and all became serologi-
cally positive. The duration between vaccination and
the positive serology ranged from 2 months to 2 years
and 8 months (mean: 10 months, median: 7 months).
Hepatitis A and B in patients with portal hypertension Mariana Nogueira de Paula Rosa y col
PVT
CLD
12.0 (9.4-13.9)
11.9 (11.5-14.7)
Age Hemoglobin (g/dL) Leukocytes (mm3) Lymphocytes (mm3)
9y3m (2-18y)
10y2m (6-14y)
4793 (1730-10,120)
5615 (4160-8720)
1458 (311-2390)
1491 (947-2177)
Table 1. Age and hematological characteristics of patients with portal vein thrombosis
(PVT) and chronic liver disease (CLD).
Values are the mean (range).
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from 3 months to 3 years and 2 months (mean: 1 year
and 7 months, median: 2 years and 2 months). The
four anti-HBs-negative patients had lymphocytopenia,
with a lymphocyte count ranging from 1012 to
1339/mm3 (mean: 1211.5/mm3, median:
1247.5/mm3). None of the anti-HBs-positive patients
presented lymphocytopenia. The duration between
vaccination and serology ranged from 3 months to 2
years and 4 months (mean: 1 year and 5 months, me-
dian: 1 year and 8 months) in patients with negative
anti-HBs, and from 4 months to 3 years and 2 months
(mean: 1 year and 10 months, median: 2 years and 2
months) in the anti-HBs-positive patients.
The four anti-HBs-negative patients (57.1%) re-
ceived a booster dose of the hepatitis B vaccine as
soon as negative results were known and all became
anti-HBs positive after the booster. All four atients
had a diagnosis of congenital liver fibrosis. The
mean time between vaccination and serology was 1
year and 5 months.
Statistical analysis for comparison of anti-HBs-
positive and anti-HBs-negative patients revealed no
significant difference in age, leukocyte counts,
lymphocyte counts, or duration between vaccina-
tion and serology in either group A or group B (Ta-
bles 2 and 3).
With respect to hepatitis B, 14 of the 16 patients
(87.5%) presented positive serology for anti-HBs
with titers ranging from 11 to 1000mIU/L (mean:
468.2, median: 349.5mIU/L). The duration bet-
ween vaccination and positive serology ranged from
3 months to 6 years and 7 months (mean: 2 years
and 7 months, median: 2 years and 10 months).
The two anti-HBs-negative patients received a
booster dose of the vaccine and showed a response
after its administration. 
Group B: Five (71.4%) of the seven patients with
chronic liver disease were male. The age and hemato-
logical characteristics of the seven patients are shown
in Table 1. Four (57.1%) patients with negative sero-
logy for hepatitis A received the vaccine at the Immu-
nobiology Sector of HC-UNICAMP and all presen-
ted positive serology after the vaccination. The dura-
tion between vaccination and serology ranged from 9
months to 2 years and 3 months (mean: 1 year and 3
months, median: 1 year). The other three (42.9%)
patients were naturally immune to hepatitis A.
All patients in this group had been vaccinated
against hepatitis B and three of them (42.9%) were an-
ti-HBs positive. The antibody titers ranged from 411
to 1000 mIU/L (mean: 638, median: 503mIU/L).
The duration between vaccination and serology ranged
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8y9m/7y
4863/4150
1520/1650
2y6m/2y7m
Anti-HBs positive Anti-HBs negative p*
Age
Leukocytes (mm3)
Lymphocytes (mm3)
Time
12y5m/12y5m
4300/4300
1016/1016
3y3m/3y3m
0.333
0.700
0.333
0.500
Table 2. Comparison between anti-HBs-positive and anti-HBs-negative patients in the
group with portal vein thrombosis (N=26).
Values are reported as mean/median. Time= time interval between vaccination and serology for hepatitis B.  *Mann-Whitney.
9y4m/9y
5390/4600
1822/1651
1y10m/2y2m
Anti-HBs positive Anti-HBs negative p*
Age
Leukocytes (/mm3)
Lymphocytes (/mm3)
Time
10y9m/10y
5785/5130
1160/1215
1y5m/1y8m
0.400
0.857
0.057
0.629
Table 3. Comparison between anti-HBs-positive and anti-HBs-negative patients in the
group with chronic liver disease (N=9).
Values are reported as mean/median. Time = time interval between vaccination and serology for hepatitis B.  *Mann-Whitney test.
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Discussion
Five (21.7%) of the 23 patients with a median age
of 13 years presented natural immunity against he-
patitis A. A low frequency of natural immunity has
also been reported by Ferreira et al.27 who found a
24% prevalence of anti-HAV IgG antibody in 59
children with chronic liver disease ranging in age
from 12 months to 16 years (mean of 7 years). The-
se percentages are considered low by us and by Fe-
rreira et al., mainly because these children belonged
to families of low socioeconomic status.
The response rate to hepatitis A vaccination was
100% in the 18 patients vaccinated in our study. Fe-
rreira et al.28 have reported, a seroconversion rate of
76% after the first vaccine dose and of 97% after
the second dose using quantitative serology tests in
34 children with chronic liver disease (17 with bi-
liary atresia, 6 with cryptogenic cirrhosis, 7 with
cirrhosis due to autoimmune hepatitis, and 4 with
other causes of cirrhosis).
In the present study, we used qualitative serologi-
cal tests for hepatitis A, which are indicated for the
detection of the disease rather than a vaccine res-
ponse. Because all the vaccinated patients were anti-
HAV positive, we inferred that the vaccine elicited
an immunological response. Most studies evaluating
the immunogenicity of hepatitis A vaccine in pa-
tients with chronic liver disease have been conduc-
ted on adult transplant patients and the results are
conflicting. Both low response rates, (6/23 - 23%
and 0/8 – nonresponse) 29,30 and a 97% response ra-
te 31 have been reported. Keeffe et al.32 evaluated the
response to hepatitis A vaccine in adults with chro-
nic liver disease and found a response rate of 94.3%
in patients infected with hepatitis C and of 97.7%
in patients infected with hepatitis B virus.
In our study, 73.9% (17/23) of the patients were
anti-HBs positive at the time of the study. The
mean time between vaccination and serology was 2
years and 4 months (median of 2 years and 3
months).
Previous studies have demonstrated lower respon-
se rates to hepatitis B vaccine in patients with chro-
nic liver disease than in healthy subjects. Aziz et al.33
observed a 72% response in adult patients who re-
ceived a vaccination series consisting of 10 double
shots after they failed to respond to the primary do-
se. Factors related to the low response rate in cirrho-
tic patients include peripheral blood lymphocytope-
nia secondary to hypersplenism, changes in the
composition of T lymphocyte subpopulations, and
inappropriate interactions among antigens, T cells,
T-cell receptors, and MHC molecules. In addition,
advanced age, disease severity and malnutrition also
play an important role in the immune response of
these patients.13,34,35 In one study, Ferrante et al.36 eva-
luated the leukocyte subpopulation in six children
with portal hypertension and observed reduction in
the absolute and relative number of CD3+ and
CD4+ T cells and cytotoxic T cells (CD8+). McGo-
vern et al.37 observed low levels of CD4+ cells in
65% of 60 adult patients with liver cirrhosis, which
was associated with splenomegaly, leukopenia, th-
rombocytopenia and anemia. In addition, they asso-
ciated reduced CD4+ cell counts with esophageal
varices and manifestations of portal hypertension.
The authors suggested that the low CD4+ counts
may be attributed to an overall sequestration of
blood cell lines because of portal hypertension. To-
kushige et al.38 found, in 24 Japanese children with
portal hypertension, reduced numbers of T helper 2
(Th2) cells in both peripheral blood and splenic
cells, but their Th1 cell counts were similar to that
of healthy subjects. Generally, Th1 cells are involved
in cellular immunity and Th2 cells play a role in hu-
moral immunity.
After immunization, anti-HBs concentration de-
clines over time. A previous study found that 15%
to 50% of vaccinated infants and children had un-
detectable levels of antibodies 9 to 15 years after the
primary vaccination.39 The presence of immunolo-
gical memory can be demonstrated by a rapid in-
crease in antibody levels after a booster dose inclu-
ding individuals with undetectable levels.40
In our study, two patients with portal vein throm-
bosis and four patients with chronic liver disease we-
re anti-HBs negative at the time of the study. Since
anti-HBs was measured years after vaccination in so-
me patients, these individuals cannot be regarded as
nonresponders to the initial vaccination. All 6 pa-
tients presented protective titers after receiving a
booster dose, demonstrating an anamnestic response.
To evaluate the effect of hypersplenism in the pa-
tients, blood counts were performed and showed no
correlation between the presence of lymphocytope-
nia and anti-HBs positivity or negativity. Thus, the
presence of hypersplenism did not seem to be related
to a decline in anti-HBs titers. The absolute number
of lymphocytes was less than 1500/mm3 in some pa-
tients, but there was no correlation between lymp-
hocytopenia and anti-HBs negativity in either group
of patients in which this correlation was analyzed.
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The two groups studied here had conditions that
make patients vulnerable to leukopenia, lymphocy-
topenia, and changes in CD4+ cell counts, all of
which may contribute to reduced response to the
vaccine. All patients vaccinated against hepatitis A
were anti-HAV positive after vaccination, thus de-
monstrating the effective immunogenicity of the
two vaccines we used. Regarding the hepatitis B vac-
cine, most patients were vaccinated at community
health centers in their towns, which made it diffi-
cult to assess the efficacy of the vaccine used. An
anamnestic response was observed in patients who
had received a booster dose. In the case of eventual
contact with the virus, memory B lymphocytes
would be stimulated to combat infection. 
In conclusion, the hepatitis A vaccines elicited a
100% response and the hepatitis B vaccine was able
to confer protection and induce an anamnestic res-
ponse in pediatric patients with portal hypertension.
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